Assessment of nationwide cancer-screening programmes

Lancet

Volumn 355, Issue 9198, 2000, Pages 80-81

  De Koning, Harry J ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER MORTALITY; CANCER SCREENING; FEMALE; FOLLOW UP; HUMAN; METHODOLOGY; NETHERLANDS; NOTE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; UNITED KINGDOM;

EID: 0034620213     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)00419-5     Document Type: Note

References (18)

1. de Haes J.C.J.M., de Koning H.J., van Oortmarssen G.J., van Agt H.M.E., de Bruyn A.E., van der Maas P.J. The impact of a breast cancer screening programme on quality-adjusted life-years. Int J Cancer. 49:1991;538-544.
2. Fentiman I. Detection and treatment of early breast cancer. 1990;Lippincott, Philadelphia.
3. Sjönell G., Ståhle L. Mammographic screening does not reduce breast cancer mortality. Läkartidningen. 96:1999;904-913. [in swedish].
4. Andersson I., Aspegren K., Janzon L.et al. Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial. BMJ. 297:1988;943-948.
5. Miller A.B., Baines C.J., To T., Wall C. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years. CMAJ. 147:1992;1477-1488.
6. Alexander F., Roberts M.M., Lutz W., Hepburn W. Randomisation by cluster and the problem of social class bias. J Epidemiol Community Health. 43:1989;29-36.
7. Tabár L., Gad A. Screening for breast cancer: the Swedish trial. Radiology. 138:1981;219-222.
8. Fagerberg G., Baldetorp L., Gröntoft O., Lundström B., Månson J.C., Nordenskjöld B. Effects of repeated mammographic screening on breast cancer stage distribution. Acta Radiologica Oncol. 24:1985;465-473.
9. de Koning H.J., Boer R., Warmerdam P.G., Beemsterboer P.M.M., van der Maas P.J. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. J Natl Cancer Inst. 87:1995;1217-1223.
10. Baines C.J., Miller A.B., Kopans D.B.et al. Canadian National Breast Screening Study: assessment of technical quality by external review. AJR Am J Roentgenol. 155:1990;743-747.
11. Narod S.A. On being the right size: a reappraisal of mammography trials in Canada and Sweden. Lancet. 349:1997;1846.
12. Andersson I., Nyström L. Mammography screening. J Natl Cancer Inst. 87:1995;1263-1264.
13. Moss S.M., Michel M., Patnick J., Johns L., Blanks R., Chamberlain J. Results from the NHS breast screening programme 1990-1993. J Med Screen. 2:1995;186-190.
14. Fracheboud J., de Koning H.J., Beemsterboer P.M.M.et al. Nation-wide breast cancer screening in The Netherlands: results of initial and subsequent screening 1990-95. Int J Cancer. 75:1998;694-698.
15. Horak E.R., Leek R., Klenk N.et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet. 340:1992;1120-1124.
16. Quinn M., Allen E. Changes in incidence of and mortality from breast cancer in England and Wales since introduction of screening. BMJ. 311:1995;1391-1395.
17. van den Akker-van Marle E., de Koning H., Boer R., van der Maas P. Reduction in breast cancer mortality due to the introduction of mass screening in the Netherlands: comparison with the United Kingdom. J Med Screen. 6:1999;30-34.
18. Hakama M., Pukkala E., Heikkila M., Kallio M. Effectiveness of the public health policy for breast cancer screening in Finland: population based cohort study. BMJ. 314:1997;864-867.